Abstract
Network-aided in silico approaches have been widely used for prediction of drug-target interactions and evaluation of drug safety to increase the clinical efficiency and productivity during drug discovery and development. Here we review the advances and new progress in this field and summarize the translational applications of several new network-aided in silico approaches we developed recently. In addition, we describe the detailed protocols for a network-aided drug repositioning infrastructure for identification of new targets for old drugs, failed drugs in clinical trials, and new chemical entities. These state-of-the-art network-aided in silico approaches have been used for the discovery and development of broad-acting and targeted clinical therapies for various complex diseases, in particular for oncology drug repositioning. In this chapter, the described network-aided in silico protocols are appropriate for target-centric drug repositioning to various complex diseases, but expertise is still necessary to perform the specific oncology projects based on the cancer targets of interest.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lavecchia A, Cerchia C (2016) In silico methods to address polypharmacology: current status, applications and future perspectives. Drug Discov Today 21:288–298
Xie L, Xie L, Kinnings SL et al (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52:361–379
Wang J, Hu K, Guo J et al (2016) Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun 7:11363
Zhao Y, Hu Q, Cheng F et al (2015) SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab 21:777–789
Cheng F, Zhao J, Zhao Z (2015) Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief Bioinform 17:642–656
Cheng F, Liu C, Lin CC et al (2015) A gene gravity model for the evolution of cancer genomes: a study of 3,000 cancer genomes across 9 cancer types. PLoS Comput Biol 11:e1004497
Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 464:993–998
Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303
Moses H 3rd, Matheson DH, Cairns-Smith S et al (2015) The anatomy of medical research: US and international comparisons. JAMA 313:174–189
DiMasi JA, Grabowski HG, Hansen RW (2015) The cost of drug development. N Engl J Med 372:1972
Cheng F, Murray JL, Zhao J et al (2016) Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis. PLoS Comput Biol 12:e1005074
Bertolini F, Sukhatme VP, Bouche G (2015) Drug repurposing in oncology--patient and health systems opportunities. Nat Rev Clin Oncol 12:732–742
Cheng F, Murray JL, Rubin DH (2016) Drug repurposing: new treatments for Zika virus infection? Trends Mol Med 22:919–921
Lu W, Yao X, Ouyang P et al (2017) Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis. J Med Chem 60:1817–1828
Cheng F, Hong H, Yang S et al (2016) Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Brief Bioinform 18:682–697
Cheng F, Zhou Y, Li J et al (2012) Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol BioSyst 8:2373–2384
Cheng F, Xu Z, Liu G et al (2010) Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem 45:3459–3471
Lu W, Cheng F, Jiang J et al (2015) FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci Rep 5:8114
Cheng F, Li W, Zhou Y et al (2013) Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). Mol BioSyst 9:1316–1325
Cheng F, Liu C, Jiang J et al (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8:e1002503
Cheng F, Zhou Y, Li W et al (2012) Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One 7:e41064
Li J, Wu Z, Cheng F et al (2014) Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology. Sci Rep 4:5576
Cheng F, Li W, Liu G et al (2013) In silico ADMET prediction: recent advances, current challenges and future trends. Curr Top Med Chem 13:1273–1289
Cheng F, Zhao Z (2014) Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am Med Inform Assoc 21:e278–e286
Zheng MW, Zhang CH, Chen K et al (2016) Preclinical evaluation of a novel orally available SRC/Raf/VEGFR2 inhibitor, SKLB646, in the treatment of triple-negative breast cancer. Mol Cancer Ther 15:366–378
Pan Y, Zheng M, Zhong L et al (2015) A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer. Mol Cancer Ther 14:407–418
Wang Y, Cheng F, Yuan X et al (2016) Dihydropyrazole derivatives as telomerase inhibitors: structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo. Eur J Med Chem 112:231–251
Zhao J, Cheng F, Wang Y et al (2016) Systematic prioritization of druggable mutations in approximately 5000 genomes across 16 cancer types using a structural genomics-based approach. Mol Cell Proteomics 15:642–656
Vuong H, Cheng F, Lin CC et al (2014) Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med 6:81
Wu Z, Lu W, Wu D et al (2016) In silico prediction of chemical mechanism-of-action via an improved network-based inference method. Br J Pharmacol 173:3372–3385
Cheng F, Jia P, Wang Q et al (2014) Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 5:3697–3710
Cheng F, Zhao J, Fooksa M et al (2016) A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. J Am Med Inform Assoc 23:681–691
Cheng F, Liu C, Shen B et al (2016) Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Syst Biol 10(Suppl 3):65
Li J, Lei K, Wu Z et al (2016) Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs. Oncotarget 7:45584–45596
Cheng F, Li W, Wu Z et al (2013) Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. J Chem Inf Model 53:753–762
Yap CW (2011) PaDEL-Descriptor: an open source software to calculate molecular descriptors and fingerprints. J Comput Chem 32:1466–1474
O'Boyle NM, Banck M, James CA et al (2011) Open babel: an open chemical toolbox. J Cheminform 3:33
Law V, Knox C, Djoumbou Y et al (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42:D1091–D1097
Yang H, Qin C, Li YH et al (2016) Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res 44:D1069–D1074
Gaulton A, Bellis LJ, Bento AP et al (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40:D1100–D1107
Liu T, Lin Y, Wen X et al (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:D198–D201
Gunther S, Kuhn M, Dunkel M et al (2008) SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 36:D919–D922
Kanehisa M, Goto S, Sato Y et al (2014) Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42:D199–D205
Hewett M, Oliver DE, Rubin DL et al (2002) PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res 30:163–165
Szklarczyk D, Santos A, von Mering C et al (2016) STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 44:D380–D384
Wang Y, Xiao J, Suzek TO et al (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 37:W623–W633
Kim Kjaerulff S, Wich L, Kringelum J et al (2013) ChemProt-2.0: visual navigation in a disease chemical biology database. Nucleic Acids Res 41:D464–D469
Seiler KP, George GA, Happ MP et al (2008) ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 36:D351–D359
von Eichborn J, Murgueitio MS, Dunkel M et al (2011) PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 39:D1060–D1066
Bulusu KC, Tym JE, Coker EA et al (2014) canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 42:D1040–D1047
Wagner AH, Coffman AC, Ainscough BJ et al (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 44:D1036–D1044
Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935
Duan Q, Flynn C, Niepel M et al (2014) LINCS canvas browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 42:W449–W460
Keshava Prasad TS, Goel R, Kandasamy K et al (2009) Human protein reference database – 2009 update. Nucleic Acids Res 37:D767–D772
Gene Ontology C (2015) Gene ontology consortium: going forward. Nucleic Acids Res 43:D1049–D1056
Coordinators NR (2016) Database resources of the national center for biotechnology information. Nucleic Acids Res 44:D7–D19
UniProt C (2015) UniProt: a hub for protein information. Nucleic Acids Res 43:D204–D212
Altschul SF, Madden TL, Schaffer AA et al (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402
Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504
Shen J, Cheng F, Xu Y et al (2010) Estimation of ADME properties with substructure pattern recognition. J Chem Inf Model 50:1034–1041
Willett P (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11:1046–1053
Cheng F, Li W, Wang X et al (2013) Adverse drug events: database construction and in silico prediction. J Chem Inf Model 53:744–752
Gene Ontology C, Blake JA, Dolan M et al (2013) Gene ontology annotations and resources. Nucleic Acids Res 41:D530–D535
Yamanishi Y, Araki M, Gutteridge A et al (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24:i232–i240
Perlman L, Gottlieb A, Atias N et al (2011) Combining drug and gene similarity measures for drug-target elucidation. J Comput Biol 18:133–145
Wu Z, Cheng F, Li J et al (2016) SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug-target interactions and drug repositioning. Brief Bioinform 18:333–347
Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50:742–754
Collins GS, de Groot JA, Dutton S et al (2014) External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol 14:40
Fang J, Wu Z, Cai C et al (2017) Quantitative and systems pharmacology. 1. In silico prediction of drug-target interactions of natural products enables new targeted cancer therapy. J Chem Inf Model. https://doi.org/10.1021/acs.jcim.7b00216 [Epub ahead of print]
Shen Q, Cheng F, Song H et al (2017) Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7,000 cancer genomes. Am J Hum Genet 100:5–20
Fang J, Liu C, Wang Q et al (2017) In silico polypharmacology of natural products. Brief Bioinform. https://doi.org/10.1093/bib/bbx045 [Epub ahead of print]
Cheng F, Jia P, Wang Q et al (2014) Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol 31:2156–2169
Zhang C, Hong H, Mendrick DL et al (2015) Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science. Biomark Med 9:1241–1252
Baryshnikova A (2016) Systematic functional annotation and visualization of biological networks. Cell Syst 2:412–421
Fang J, Cai C, Wang Q et al (2017) Systems pharmacology-based discovery of natural products for precision oncology through targeting cancer mutated genes. CPT Pharmacometrics Syst Pharmacol 6:177–187
Fang JS, Gao L, Ma HL et al (2017) Quantitative and systems pharmacology 3. Network-based identification of new targets for natural products enables potential uses in aging-associated disorders. Front Pharmacol 8:747
Zhao J, Cheng F, Zhao Z (2017) Tissue-specific signaling networks rewired by major somatic mutations in human cancer revealed by proteome-wide discovery. Cancer Res 77:2810–2821
Lu W, Cheng F, Yan W et al (2017) Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene 36:4719–4731
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Cheng, F. (2019). In Silico Oncology Drug Repositioning and Polypharmacology. In: Krasnitz, A. (eds) Cancer Bioinformatics. Methods in Molecular Biology, vol 1878. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8868-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8868-6_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8866-2
Online ISBN: 978-1-4939-8868-6
eBook Packages: Springer Protocols